Microbial metabolite 5-formamidoimidazole-4-carboxamide ribotide targets METTL1 to inhibit m7G modification of BRCA1 mRNA to inhibit high-grade serous ovarian cancer
The vaginal microbial metabolite 5-formamidoimidazole-4-carboxamide ribotide reduces BRCA1 expression and slows HGSOC progression by modifying BRCA1 m7G through METTL1, suggesting its potential as an HGSOC treatment.
Authors
- Sili He
- Lixing Chen
Institutions
- Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1186/s10020-025-01396-y
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hunan Province